All patients, n = 146 | No impairment, n = 58 (39.7%) | Cognitive impairment, n = 88 (60.3%) | p-value | |
---|---|---|---|---|
Clinical parameters | ||||
Age (years) | 63.8 (10.8) | 62.1 (11.4) | 64.9 (10.3) | 0.129 |
Female sex | 22 (15.1%) | 6 (10.3%) | 16 (18.2%) | 0.195 |
Body mass index (kg/m2) | 29.1 (5.2) | 29.5 (6.4) | 28.8 (4.3) | 0.451 |
Systolic blood pressure (mmHg) | 138.1 (19.9) | 134.7 (19.3) | 140.4 (20.1) | 0.090 |
Diastolic blood pressure (mmHg) | 81.0 (11.0) | 80.0 (11.4) | 81.8 (10.9) | 0.354 |
Heart rate (beats per minute) | 64.5 (10.4) | 63.8 (10.8) | 65.1 (10.3) | 0.452 |
Diabetes mellitus type IIa | 42 (28.8%) | 16 (27.6%) | 26 (29.5%) | 0.798 |
Arterial hypertensionb | 116 (79.5%) | 44 (75.9%) | 72 (81.8%) | 0.383 |
Hyperlipidemiac | 105 (71.9%) | 45 (77.6%) | 60 (68.2%) | 0.216 |
(Former) smoking | 88 (60.3%) | 41 (70.7%) | 47 (53.4%) | 0.037 |
Apparent dementia | 0 (0.0%) | – | – | – |
Atrial fibrillation/atrial flutter | 33 (22.6%) | 13 (22.4%) | 20 (22.7%) | 0.965 |
Coronary artery disease | 100 (68.5%) | 38 (65.5%) | 62 (70.5%) | 0.530 |
History of myocardial infarction | 80 (54.8%) | 32 (55.2%) | 48 (54.5%) | 0.941 |
History of coronary artery bypass grafting | 36 (24.7%) | 13 (22.4%) | 23 (26.1%) | 0.610 |
Peripheral artery disease | 14 (9.6%) | 6 (10.3%) | 8 (9.1%) | 0.801 |
Angiotensin-converting enzyme inhibitor | 86 (58.9%) | 35 (60.3%) | 51 (58.0%) | 0.774 |
Beta-blocker | 131 (89.7%) | 51 (87.9%) | 80 (90.9%) | 0.562 |
Aldosteron antagonist | 54 (37.0%) | 20 (34.5%) | 34 (38.6%) | 0.611 |
Diuretics | 80 (54.8%) | 29 (50.0%) | 51 (58.0%) | 0.345 |
Acetylsalicylic acid | 80 (54.8%) | 28 (48.3%) | 52 (59.1%) | 0.199 |
Coumadin or novel oral anticoagulant | 45 (30.8%) | 16 (27.6%) | 28 (31.8%) | 0.586 |
Parameters of cardiac and renal dysfunction | ||||
Left ventricular ejection fraction (%) | 42.5 (8.2) | 41.7 (7.8) | 43.0 (8.4) | 0.337 |
Left atrial volume index (ml/min) | 42.0 (17.5) | 40.6 (14.1) | 42.6 (18.9) | 0.481 |
6-min walk test (m) | 391.5 (99.3) | 417.2 (97.6) | 375.0 (97.5) | 0.014 |
NT-proBNP (pg/ml) | 1330 (2041) | 1192 (2409) | 1422 (1764) | 0.515 |
eGFR (ml/min) | 66.5 (19.4) | 69.4 (19.5) | 64.6 (19.2) | 0.149 |
Cognitive test battery | ||||
Intensity of attention (T-score) | 41.8 (7.5) | 47.2 (5.6) | 38.3 (6.5) | < 0.001 |
Visual/verbal memory (T-score) | 45.3 (6.2) | 50.3 (6.7) | 42.0 (6.9) | < 0.001 |
Executive functions (T-score) | 45.4 (5.3) | 47.8 (4.6) | 43.9 (5.2) | < 0.001 |
Selectivity of attention (T-score) | 45.3 (7.9) | 46.5 (5.7) | 44.4 (6.4) | 0.052 |
Working memory (T-score) | 46.2 (8.5) | 49.3 (8.0) | 44.2 (8.3) | < 0.001 |
Visual/verbal fluency (T-score) | 44.8 (7.1) | 47.6 (5.6) | 43.0 (7.6) | < 0.001 |
Magnetic resonance imaging | ||||
WMH volume (mm3) | 4.36 (6.20) | 3.88 (4.58) | 4.67 (7.07) | 0.452 |
Cerebral atrophy score (1–8) | 3.25 (1.26) | 3.15 (1.38) | 3.31 (1.19) | 0.447 |
Hippocampal atrophy score (0–4) | 2.04 (0.90) | 1.88 (0.86) | 2.14 (0.91) | 0.085 |
Serum biomarkers | ||||
Neurofilament light chain (pg/ml) | 34.0 (27.8) | 30.7 (23.7) | 36.2 (30.1) | 0.247 |
Phosphorylated tau protein (pg/ml) | 1.69 (1.33) | 1.66 (0.88) | 2.16 (1.53) | 0.014 |